Home › Funds › Sarissa Capital Management LP › CYTK
Sarissa Capital Management LP position in CYTK
CYTOKINETICS INC · Health Care
Sarissa Capital Management LP reported holding 228,623 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$15.1M, representing 9.84% of its reported portfolio and ranking #6 among its reported holdings. Sarissa Capital Management LP has disclosed CYTK holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Sarissa Capital Management LP's CYTK position evolved
Sarissa Capital Management LP first disclosed a stake in CYTK in Q1 2024 at 300,000 shares (US$21.0M). The position peaked in Q2 2024 at 1,110,000 shares, worth US$60.1M. Across 11 filings, Sarissa Capital Management LP increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 228,623 shares valued at US$15.1M. Notable position changes include a 270% increase in Q2 2024 (shares fell 3% over the following quarter), a 33% trim in Q4 2025 (shares rose 4% over the following quarter), a 42% trim in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 300.00K | $21.03M | New |
| Q2 2024 | 1.11M | $60.14M | Add |
| Q3 2024 | 1.11M | $58.61M | Hold |
| Q4 2024 | 833.80K | $39.22M | Reduce |
| Q1 2025 | 600.00K | $24.11M | Reduce |
| Q2 2025 | 588.36K | $19.44M | Reduce |
| Q3 2025 | 588.36K | $32.34M | Hold |
| Q4 2025 | 396.36K | $25.18M | Reduce |
| Q1 2026 | 228.62K | $15.07M | Reduce |
| Q2 2026 | 228.62K | $19.48M | Hold |
| Q3 2026 | 228.62K | $15.07M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 36 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.25B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.91M sh · $1.25B · Q3 2026
- Avoro Capital Advisors LLC 4.90M sh · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $47.11M · Q3 2026
More on Sarissa Capital Management LP
FAQ
How long has Sarissa Capital Management LP held CYTK?
Sarissa Capital Management LP has disclosed CYTK holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Sarissa Capital Management LP's current position in CYTK?
As of Q3 2026, Sarissa Capital Management LP holds 228.62K shares of CYTK (CYTOKINETICS INC), valued at $15.07M, representing 9.84% of its reported portfolio and ranking #6.
Has Sarissa Capital Management LP been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Sarissa Capital Management LP held unchanged its position in CYTK. The position peaked in Q2 2024 at 1.11M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.